SITE006-0155

SITE006 (GBR) › SITE006-0155

SITE006-0155

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-03-08

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 56); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 7); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-18 (study day 4); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.